Sylvester presents latest cancer research at ASH Annual Meeting

December 02, 2015

MIAMI, December 2, 2015 -- Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will present a selection of the latest advances in hematology research at this year's American Society of Hematology (ASH) Annual Meeting, December 5-8, at the Orange County Convention Center in Orlando, Fla.

Reporters interested in interviewing Sylvester researchers on-site at the conference should contact Patrick Bartosch at (201) 469-6408 or

Highlights of research presented by Sylvester researchers include:

Oral Presentations

Monday, December 7

The small molecule Img-98, a potent and selective inhibitor of the lysine demethylase Lsd-1, effectively augments the pro-differentiation effects of all-trans-retinoic acid (ATRA) in a pre-clinical model of acute myeloid leukemia (AML)
Ronan Swords; presentation #460; 7:45 a.m.; W109, Level 1

Grb2 directly interacts with HGAL and ameliorates its effects on B-cell receptor signaling
Izidore Lossos; presentation #702; 4 p.m.; W311EFGH, Level 3

Poster Presentations

Saturday, December 5

Pharmacokinetics of red cell microparticles (RMP) in rabbits and rats: effects of administration, regimen and label of assay
Wenche Jy; poster #1146; 5:30-7:30 p.m.; Hall A, Level 2

Inhibition of the PI3K/AKT/mTOR pathway leads to down regulation of c-Myc and overcomes resistance to all-trans-retinoic acid (ATRA) in acute myeloid leukemia
Ronan Swords; poster #1363; 5:30-7:30 p.m.; Hall A, Level 2

The combination of belinostat with zidovudine for treatment of HTLV-I-related adult T-cell leukemia-lymphoma
Juan Carlos Ramos; poster #1562; 5:30-7:30 p.m.; Hall A, Level 2

Sunday, December 6

A patient-specific ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy
Ronan Swords; poster #1352; 5:30-7:30 p.m.; Hall A, Level 2

The BET bromodomain inhibitors EP11313 and EP11336 have potent anti-leukemic activity in acute myeloid leukemia (AML) and augment the effects of all-trans-retinoic acid (ATRA) in vitro
Ronan Swords; poster #2552; 6-8 p.m.; Hall A, Level 2

Monday, December 7

Elevated red cell microparticles (RMP) in hematologic and thrombotic disorders
Wenche Jy; poster #3553; 6-8 p.m.; Hall A, Level 2

In acute myeloid leukemia (AML), targeting the histone methyltransferase EZH2 promotes differentiation, impairs clonogenic survival and augments the anti-leukemic effects of the retinoid, all-trans-retinoic acid (ATRA)
Ronan Swords; poster #3786; 5-8 p.m.; Hall A, Level 2

FBXO10 targets HGAL for degradation
Izidore Lossos; poster #3904; 6-8 p.m.; Hall A, Level 2

Join the conversation about this year's ASH Annual Meeting by using the hashtag #ASH2015 on Facebook, Twitter and Instagram.
About Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System and the University of Miami Miller School of Medicine, is among the nation's leading cancer centers, and South Florida's only Cancer Center of Excellence. With the combined strength of more than 115 cancer researchers and 130 cancer specialists, Sylvester discovers, develops and delivers more targeted therapies leading to better outcomes - providing the next generation of cancer clinical care - precision cancer medicine - to each patient. Our comprehensive diagnostics coupled with teams of scientific and clinical experts who specialize in just one type of cancer, enable us to better understand each patient's individual cancer and develop treatments that target the cells and genes driving the cancer's growth and survival. At Sylvester, patients have access to more treatment options and more cancer clinical trials than most hospitals in the southeastern United States. To better serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities in Miami, Kendall, Hollywood, Plantation, Deerfield Beach and Coral Springs, with plans to open in Coral Gables in 2016. For more information, visit

University of Miami Miller School of Medicine

Related Acute Myeloid Leukemia Articles from Brightsurf:

Young survivors of acute myeloid leukemia have long-term complications from treatment
Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found.

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

ASH releases new clinical practice guidelines on acute myeloid leukemia in older adults
Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI.

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation
The cover for issue 25 of Oncotarget features Figure 8, 'BI-D1870 in combination with vincristine increase metaphase arrest and apoptosis synergistically,' by Chae, et al.

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia
Researchers from the Josep Carreras Leukaemia Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease.

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

Read More: Acute Myeloid Leukemia News and Acute Myeloid Leukemia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to